WO2003028624A3 - Compositions de levothyroxine et procedes - Google Patents

Compositions de levothyroxine et procedes Download PDF

Info

Publication number
WO2003028624A3
WO2003028624A3 PCT/US2002/025752 US0225752W WO03028624A3 WO 2003028624 A3 WO2003028624 A3 WO 2003028624A3 US 0225752 W US0225752 W US 0225752W WO 03028624 A3 WO03028624 A3 WO 03028624A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
sodium
making
levothyroxine
Prior art date
Application number
PCT/US2002/025752
Other languages
English (en)
Other versions
WO2003028624A2 (fr
Inventor
G Andrew Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Original Assignee
King Pharmaceuticals Inc
G Andrew Franz
Elaine A Strauss
Phillip A Dimenna
Rocco L Gemma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Inc, G Andrew Franz, Elaine A Strauss, Phillip A Dimenna, Rocco L Gemma filed Critical King Pharmaceuticals Inc
Priority to AU2002362468A priority Critical patent/AU2002362468A1/en
Publication of WO2003028624A2 publication Critical patent/WO2003028624A2/fr
Publication of WO2003028624A3 publication Critical patent/WO2003028624A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Abstract

La présente invention porte en général sur des compositions pharmaceutiques et sur leurs procédés de fabrication et d'administration. Selon une forme d'exécution, l'invention se caractérise par des compositions pharmaceutiques stabilisées qui comprennent des ingrédients actifs d'un point de vue pharmaceutique tels que lévothyroxine (T4) sodium et liothyronine (T3) sodium (médicaments de l'hormone thyroïdienne), de préférence de forme galénique solide à libération immédiate. L'invention porte également sur des procédés de fabrication et d'utilisation de ces compositions stabilisées et à libération immédiate.
PCT/US2002/025752 2001-08-14 2002-08-14 Compositions de levothyroxine et procedes WO2003028624A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362468A AU2002362468A1 (en) 2001-08-14 2002-08-14 Levothyroxine compositions and methods

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US31211401P 2001-08-14 2001-08-14
US31218401P 2001-08-14 2001-08-14
US31228701P 2001-08-14 2001-08-14
US31248301P 2001-08-14 2001-08-14
US31227301P 2001-08-14 2001-08-14
US31211301P 2001-08-14 2001-08-14
US60/312,114 2001-08-14
US60/312,113 2001-08-14
US60/312,184 2001-08-14
US60/312,273 2001-08-14
US60/312,287 2001-08-14

Publications (2)

Publication Number Publication Date
WO2003028624A2 WO2003028624A2 (fr) 2003-04-10
WO2003028624A3 true WO2003028624A3 (fr) 2003-11-06

Family

ID=27617967

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2002/025854 WO2003061557A2 (fr) 2001-08-14 2002-08-14 Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees
PCT/US2002/025752 WO2003028624A2 (fr) 2001-08-14 2002-08-14 Compositions de levothyroxine et procedes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025854 WO2003061557A2 (fr) 2001-08-14 2002-08-14 Compositions pharmaceutiques a base de levothyroxine, methodes de fabrication et d'administration associees

Country Status (2)

Country Link
AU (1) AU2002341555A1 (fr)
WO (2) WO2003061557A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645526B2 (en) 2001-11-13 2003-11-11 Mylan Pharmaceuticals, Inc. Storage stable thyroxine active drug formulations and methods for their production
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
WO2005051298A2 (fr) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
CA2606499C (fr) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Composes thyromimetiques utilises pour traiter les maladies hepatiques graisseuses
KR20190104524A (ko) 2016-11-21 2019-09-10 바이킹 테라퓨틱스 인코포레이티드 당원축적질환의 치료 방법
KR102600115B1 (ko) 2017-06-05 2023-11-09 바이킹 테라퓨틱스 인코포레이티드 섬유증 치료를 위한 조성물
EP3768690A4 (fr) 2018-03-22 2021-11-24 Viking Therapeutics, Inc. Formes cristallines et procédés de production de formes cristallines d'un composé
CA3164402A1 (fr) * 2020-01-13 2021-07-22 Jaydeep VAGHASHIYA Compositions a liberation prolongee comprenant de la liothyronine
US11964048B2 (en) 2020-12-18 2024-04-23 Amneal Complex Products Research Llc Sustained release compositions comprising liothyronine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997017951A1 (fr) * 1995-11-14 1997-05-22 Knoll Pharmaceutical Company Preparations d'hormones thyroidiennes stabilisees et procede de fabrication correspondant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753254A (en) * 1994-02-01 1998-05-19 Knoll Aktiengesellschaft Therapeutic agents containing thyroid hormones
US6190696B1 (en) * 1998-06-08 2001-02-20 Pieter J. Groenewoud Stabilized thyroxine medications

Also Published As

Publication number Publication date
WO2003061557A3 (fr) 2003-11-06
AU2002341555A1 (en) 2003-09-02
WO2003028624A2 (fr) 2003-04-10
WO2003061557A2 (fr) 2003-07-31

Similar Documents

Publication Publication Date Title
HK1096034A1 (en) A solid dosage form comprising a fibrate
WO2002017918A3 (fr) Formulations a liberation prolongee pour les secretagogues de l'hormone de croissance
BR0003158A (pt) Formulação de dosagem oral de derretimentoinstantâneo
BG66093B1 (bg) Състави с контролирано освобождаване, съдържащи нимесулид
MY151468A (en) Controlled release solid preparation
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2002074247A3 (fr) Formulations pharmaceutiques a liberation prolongee
WO2003002136A3 (fr) Formulation stable de glp-1 modifie
EA017764B8 (ru) Фармацевтическая композиция, способ ее получения и способ лечения вирусных заболеваний с ее использованием
HK1080364A1 (en) Oral pharmaceutical forms of liquid drugs having improved bioavailability
TW200633716A (en) Compositions and methods for stabilizing active pharmaceutical ingredients
MX2009003030A (es) Forma galenita para la administracion por via transmucosa de principios activos.
AU2002231654A1 (en) Pharmaceutical paste comprising an acid-labile active ingredient
MY151470A (en) Controlled release solid preparation
EE03089B1 (et) Ibuprofeeni sisaldav kihisev ravimpreparaat ja selle valmistamise meetod
AP2003002763A0 (en) Controlled release formulations for oral administration
MX2010004556A (es) Formulacion farmaceutica de acido clavulanico.
IL150528A0 (en) Ibuprofen containing active agent preparation
WO2003028624A3 (fr) Compositions de levothyroxine et procedes
WO2002015933A3 (fr) Combinaison
MXPA03002807A (es) Estabilizacion de formulaciones solidas de farmacos.
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
CY1107295T1 (el) Σταθεροποιηση στερεων φορμουλων φαρμακων του θυρεοειδους
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
WO2003013441A3 (fr) Compositions de levothyroxine et procedes connexes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP